H.pylori infection
Conditions
Interventions
High dose Cranberry juice:2 doses in am and pm - Total of 4 doses of Cranberry juice per day
Low dose Cranberry juice:1 dose in am and pm - Total of 2 doses of Cranberry juice per day
High dose Placebo juice:2 doses in am and pm - Total of 4 doses of Placebo juice per day
High dose cranberry powder:2 doses in am and pm - Total of 4 doses of cranberry powder per day
Low dose cranberry powder:1 dose in am and pm - Total of 2 doses of cranberry powder per day
High dose placebo powder:2 doses in am and pm - Total of 4 doses of placebo powder per day
Sponsors
Peking University Cancer Hospital & Institute, Beijing Institute for Cancer Research
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Must test positive for Helicobacter pylori in urea breath test. (Ethical issues of recruiting H. pylori-positive subjects: relatively short study period not likely to be deleterious to health. Possibly offer cranberry non-responders antibiotic treatment at conclusion of the study): 1. Willingness to complete questionnaires, records, and diaries associated with the study and to complete all urea breath testing procedures; 2. Willingness to provide medical history, including family history of ulcers and stomach cancer; 3. Has given voluntary, written, informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Subjects diagnosed with an existing ulcer; 2. Subjects who are taking antibiotics currently or within the last 6 months for ulcers or other bacterial infections; 3. Subjects who have been treated for H. pylori with antibiotics; 4. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial; 5. Subject has a known allergy to the test materials active or inactive ingredients, as reported by subject; 6. Subjects with unstable or serious medical conditions, including stomach cancer; 7. Subjects taking blood thinners (Warfarin, Coumadin); 8. Alcohol or drug abuse within 6 months; 9. Individuals who are cognitively impaired and/or who are unable to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 15% initial eradication; | — |
Countries
China
Contacts
Public ContactKaifeng Pan
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing Institute for Cancer Research
Outcome results
None listed